Posted by Michael Wonder on 05 Jul 2023
Olaparib for the maintenance treatment of adults with relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after two or more courses of platinum-based chemotherapy
5 July 2023 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the maintenance treatment of adults with relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after two or more courses of platinum-based chemotherapy.
This is a review of TA620.
